{"type":"img","src":"//cdn.quv.kr/sxzvacztd/up/65fbebb05625a_1920.jpeg","height":200}
  • COMPANY
  • PRODUCT
  • NEWS
  • CONTACT
  • {"google":["Montserrat"],"custom":["Noto Sans KR","Kukdetopokki"]}
    ×
     
     
    섹션 설정
    {"type":"img","src":"https://cdn.quv.kr/sxzvacztd%2Fup%2F66a312957f303_1920.jpg","height":40}
  • COMPANY
  • PRODUCT
  • NEWS
  • CONTACT
  • Description and composition

    Medy-Tox Inc. is the first company in the world to develop a triple botulinum toxin formulation.

    Coretox This is a new botulinum toxin type A product designed to reduce the risk of drug resistance, an ongoing concern after repeated injections.

    It is manufactured by eliminating non-toxic proteins that are not related to efficacy and refining only neurotoxins. Due to the nature of regular injections, patients may develop resistance to Botox treatment, depending on the number, duration and dose of administration.

    {"google":["Montserrat"],"custom":["Noto Sans KR","Kukdetopokki"]}{"google":["Montserrat","Roboto","PT Sans"],"custom":["Noto Sans KR","Kukdetopokki"]}
    {"google":[],"custom":["Noto Sans KR"]}